Allena Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing oral enzyme therapeutics to treat patients with metabolic and kidney disorders. Co. is focused on metabolic disorders that result in excess accumulation of certain metabolites that stimulate inflammation, damage the kidney, and potentially lead to chronic kidney disease (CKD), and end-stage renal disease. Co.'s product candidate, ALLN-346, is an orally administered, urate degrading enzyme for patients with hyperuricemia and gout in the setting of improved CKD. Co. has conducted a Phase 1 program, including both a single-ascending dose and multiple-ascending dose study in healthy volunteers. We show 24 historical shares outstanding datapoints in our coverage of ALNA's shares outstanding history.
Understanding the changing numbers of ALNA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ALNA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ALNA by allowing them to research ALNA shares outstanding history
as well as any other stock in our coverage universe. |
Free ALNA Email Alerts:
Video: Shares Outstanding Importance
